IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company” category of the 2018 OBN Awards
London, 22 August 2018– IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has been shortlisted as a finalist in the 2018 OBN Awards in the “Best Start-up Biotech Company” category.
The “Best Start-up Biotech Company” award recognises a UK registered start-up biotech company that was incorporated on or after 1 June 2016, is making an impact on the industry via significant news flow, has successfully raised seed or Series A fundraising, is conducting early clinical trial activity and can demonstrate clear evidence of early stage implementation of a robust business plan.
2018 marks the 10th Anniversary of the OBN Awards, which recognise the leading lights of the life sciences industry in the UK. The winners will be announced at the OBN Awards evening on Thursday 11 October at the Examination Schools in Oxford.
Dr Tim Wilson, Chief Executive Officer of IGEM Therapeutics, commented: “We are delighted that IGEM Therapeutics has been shortlisted as a finalist in the “Best Start-up Biotech Company” category at the OBN Awards. To be considered for these prestigious awards is recognition of our efforts to develop novel immunoglobulin E (IgE) antibodies for the treatment of cancer.”